Flurpiridaz F 18: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
|authorTag={{PVS}}
|authorTag={{PVS}}
|genericName=flurpiridaz f-18
|genericName=flurpiridaz f-18
|aOrAn=a
|aOrAn=an
|drugClass=radioactive diagnostic
|drugClass=analog of the mitochondrial complex 1 (MC-1) inhibitor
|indicationType=treatment
|indicationType=treatment
|indication=FLYRCADO is a radioactive diagnostic drug that is FDA approved for the positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
|indication=positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
|adverseReactions=Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are *dyspnea,
*headache,
*angina pectoris,
*chest pain,
*fatigue,
*ST segment changes,
*flushing,
*nausea,
*abdominal pain,
*dizziness, and
*arrhythmia.
|blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>'''
|blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>'''
|blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content)
|blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content)

Revision as of 15:04, 12 April 2025

Flurpiridaz F 18
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parth Vikram Singh, MBBS[2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Flurpiridaz F 18 is an analog of the mitochondrial complex 1 (MC-1) inhibitor that is FDA approved for the treatment of positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.. Common adverse reactions include Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are *dyspnea,

  • headache,
  • angina pectoris,
  • chest pain,
  • fatigue,
  • ST segment changes,
  • flushing,
  • nausea,
  • abdominal pain,
  • dizziness, and
  • arrhythmia..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Flurpiridaz F 18 FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Flurpiridaz F 18 in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Flurpiridaz F 18 in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Flurpiridaz F 18 FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Flurpiridaz F 18 in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Flurpiridaz F 18 in pediatric patients.

Contraindications

There is limited information regarding Flurpiridaz F 18 Contraindications in the drug label.

Warnings

There is limited information regarding Flurpiridaz F 18 Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Flurpiridaz F 18 Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Flurpiridaz F 18 Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Flurpiridaz F 18 Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Flurpiridaz F 18 in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Flurpiridaz F 18 in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Flurpiridaz F 18 during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Flurpiridaz F 18 in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Flurpiridaz F 18 in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Flurpiridaz F 18 in geriatric settings.

Gender

There is no FDA guidance on the use of Flurpiridaz F 18 with respect to specific gender populations.

Race

There is no FDA guidance on the use of Flurpiridaz F 18 with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Flurpiridaz F 18 in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Flurpiridaz F 18 in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Flurpiridaz F 18 in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Flurpiridaz F 18 in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Flurpiridaz F 18 Administration in the drug label.

Monitoring

There is limited information regarding Flurpiridaz F 18 Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Flurpiridaz F 18 and IV administrations.

Overdosage

There is limited information regarding Flurpiridaz F 18 overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Flurpiridaz F 18 Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Flurpiridaz F 18 Mechanism of Action in the drug label.

Structure

There is limited information regarding Flurpiridaz F 18 Structure in the drug label.

Pharmacodynamics

There is limited information regarding Flurpiridaz F 18 Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Flurpiridaz F 18 Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Flurpiridaz F 18 Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Flurpiridaz F 18 Clinical Studies in the drug label.

How Supplied

There is limited information regarding Flurpiridaz F 18 How Supplied in the drug label.

Storage

There is limited information regarding Flurpiridaz F 18 Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Flurpiridaz F 18 |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Flurpiridaz F 18 |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Flurpiridaz F 18 Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Flurpiridaz F 18 interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Flurpiridaz F 18 Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Flurpiridaz F 18 Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.